09.02.2015 Views

Stability of Drugs and Dosage Forms Sumie Yoshioka

Stability of Drugs and Dosage Forms Sumie Yoshioka

Stability of Drugs and Dosage Forms Sumie Yoshioka

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

132 Chapter 2 • Chemical <strong>Stability</strong> <strong>of</strong> Drug Substances<br />

Scheme 77. Reaction pathway leading to melphalan degradation through a polar cyclic ethyleneimmonium<br />

intermediate. (Reproduced from Ref. 543 with permission.)<br />

β -CD, thalidomide by HP- β -CD, 539 tauromustine by HP-α-CD, 540 <strong>and</strong> medroxyprogesterone<br />

acetate <strong>and</strong> megestrol acetate by HP-β -CD <strong>and</strong> methyl-β -CD. 541 The stabilizing<br />

effect <strong>of</strong> β -CD against the oxidation <strong>of</strong> 2-[8-methyl-10,11-dihydro-11-<br />

oxodibenz[b,ƒ]oxepin-2-yl]propionic acid in ointments has also been reported. 542<br />

Recently, Ma et al. 543 studied the stability <strong>of</strong> the very unstable alkylating agent<br />

melphalan in the presence <strong>of</strong> (SBE) 7M -β-CD <strong>and</strong> HP-β -CD. Melphalan undergoes an<br />

intramolecular displacement reaction through a very polar cyclic ethyleneimmonium intermediate<br />

(Scheme 77). The very polar transition state leading to this intermediate involves<br />

considerable charge separation. Both (SBE), 7M -β-CD <strong>and</strong> HP-β -CD stabilized melphalan to<br />

chemical degradation. 543 What is interesting in this case is that both (SBE) 7M -β-CD <strong>and</strong><br />

HP- β -CD have similar binding constants for melphalan <strong>and</strong> the same K values, as defined<br />

in Scheme 76, but k c was significantly smaller in the case <strong>of</strong> (SBE) 7M -β-CD (Table 7). One<br />

would intuitively feel that similar binding constants should yield similar positional binding<br />

in the cyclodextrin cavity <strong>and</strong> perhaps similar k c values. Ma et al. 543 were able to demonstrate<br />

that the melphalan bound to (SBE) 7M -β-CD was in a more hydrophobic environment <strong>and</strong><br />

that there was a small but significant difference in the position <strong>of</strong> binding <strong>of</strong> melphalan to<br />

(SBE) 7M -β-CD versus HP-β -CD.<br />

Although the degradation-inhibiting effects <strong>of</strong> CDs <strong>and</strong> their derivatives through<br />

complex formation can be used as a method for stabilizing pharmaceuticals, CDs <strong>and</strong> their<br />

derivatives may also enhance drug degradation, depending on the reaction mechanisms <strong>and</strong><br />

the steric arrangement <strong>of</strong> the drug in the complex. For example, β -CD inhibits the alkaline<br />

hydrolysis <strong>of</strong> benzocaine (ethyl p-aminobenzoate) 544 but enhances that <strong>of</strong> aspirin (Table<br />

8). 545 This has been explained by assuming that complex formation protects the ester bond<br />

<strong>of</strong> ethyl p-aminobenzoate from attack by the hydroxide ion nucleophile. In the case <strong>of</strong><br />

Table 7. Estimated Values <strong>of</strong> K, k ƒ, <strong>and</strong> k c for the Degradation <strong>of</strong> Melphalan at 25°C (pH 7.5) in<br />

the Presence <strong>of</strong> (SBE) 7M-β -CD <strong>and</strong> HP- β -CD, in Accordance with Scheme 76 a<br />

Cyclodextrin K (M -1 ) kƒ ( h-1 ) kc ( h-1 ) kƒ/kc<br />

(SBE)7M-β-CD 360 0.2 1.8 x 10 -3 114<br />

HP-β -CD 382 0.2 1.1 x 10 -2 20<br />

a<br />

Reference 543.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!